Heart failure & cardiomyopathies
Effects of Dapagliflozin According to QRS Duration Across the Spectrum of Left Ventricular Ejection Fraction: An Analysis of DAPA-HF and DELIVER
Authors' conclusion
Prolongation of QRS duration is associated with worse outcomes irrespective of HF phenotype. Dapagliflozin reduced the risk of the primary outcome, regardless of QRS duration, in DAPA-HF and DELIVER.
Study context
- Population
- Heart failure (HF) patients across the left ventricular ejection fraction (LVEF) spectrum (HFrEF and HFmrEF/HFpEF), excluding paced rhythm and CRT4,008 HFrEF, 5816 HFmrEF/HFpEF
- Comparison
- Dapagliflozin vs placebo, by QRS duration
- Primary endpoint
- CV death or worsening HF
- Follow-up
- Median 23 months
Methodological detailspooled analysis, subgroup analysis by QRS duration
- Pooled analysis
- Subgroup analysis by QRS duration
Primary result
As reported in the abstract
CV death or worsening HF, dapagliflozin vs placebo by QRS duration
Dapagliflozin vs PlaceboHazard ratio (95% CI)
QRS <120 ms
0.75(0.67–0.85)
QRS 120-149 ms
0.79(0.65–0.96)
QRS ≥150 ms
0.89(0.70–1.13)
Further findings
per 100 patient-years
<120
9.2 (95% CI 8.7–9.7) per 100 patient-years
120-149
14.3 (95% CI 13.0–15.7) per 100 patient-years
≥150
15.9 (95% CI 14.1–17.9) per 100 patient-years
- Gradient in event rates observed both in HFrEF and HFmrEF/HFpEF
Original publication
Effects of Dapagliflozin According to QRS Duration Across the Spectrum of Left Ventricular Ejection Fraction: An Analysis of DAPA-HF and DELIVER. Eur J Heart Fail. Published 17 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →